<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01176890</url>
  </required_header>
  <id_info>
    <org_study_id>Truncated mealtest (AP)</org_study_id>
    <nct_id>NCT01176890</nct_id>
  </id_info>
  <brief_title>Intact Vagal Innervation and Glucagon-like Peptide-1 (GLP-1) Effects</brief_title>
  <official_title>The Significance of Intact Vagal Innervation for the GLP-1 Induced Inhibition of Gastric Emptying, Appetite and Food Intake</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Gentofte, Copenhagen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Copenhagen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Gentofte, Copenhagen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to investigate the role of transmission via the vagal nerve for the
      effect of Glucagon-like peptide-1 (GLP-1) in respect to gastric emptying, appetite and food
      intake.

      The hypothesis is that a great deal of the effects of GLP-1 is mediated via the nervous
      system and for this reason the researchers will investigate individuals with and without
      intact nervous supply.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      GLP-1 is a potent enterogastron and incretin hormone. It is rapidly inactivated by dipeptidyl
      peptidase IV so only 10-15% enters the systemic circulation. This has led to the hypothesis
      that GLP-1 interact locally with afferent sensory nerve fibers. We investigated the role of
      intact vagal innervations on the effect of GLP-1 on the food intake, gastric emptying (GE)
      and appetite.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>July 2008</start_date>
  <completion_date type="Anticipated">December 2012</completion_date>
  <primary_completion_date type="Actual">August 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Gastric emptying</measure>
    <time_frame>four hours</time_frame>
    <description>Gastric emptying will be assessed using a liquid meal with 1.5 g paracetamol added and continuous blood sampling for measuring paracetamol concentration during four hours</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Appetite</measure>
    <time_frame>four hours</time_frame>
    <description>Hunger, satiation, and fullness will be assessed before, during and after a liquid meal with 1.5 g paracetamol added using a visual analog scale (VAS)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Food intake</measure>
    <time_frame>five hours</time_frame>
    <description>After the liquid meal test, the volunteers will be offered a meal to assessed their ad libitum food intake</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>plasma glucose</measure>
    <time_frame>four hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>serum insulin and c-peptide</measure>
    <time_frame>four hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>plasma glucagon</measure>
    <time_frame>four hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>plasma GLP-1</measure>
    <time_frame>four hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>endogenous GLP-1</measure>
    <time_frame>four hours</time_frame>
    <description>endogenous GLP-1 will be assessed as plasma GLP-2 concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>plasma GIP</measure>
    <time_frame>four hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>serum paracetamol</measure>
    <time_frame>four hours</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Vagotomy, Truncal</condition>
  <arm_group>
    <arm_group_label>Vago</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Truncally vagotomized subjects (due to duodenal ulcer operation)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cardia</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>truncally vagotomized subjects (due to esophagus resection)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy controls</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy control subjects</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GLP-1</intervention_name>
    <description>1.2 pmol/kg/min GLP-1 will be infused intravenously during the four hour meal test (100 g Ny NAN1 and 1.5 g paracetamol dissolved in 300 ml water) ingested over 10 minutes.
After four hours an ad libitum meal will be supplied</description>
    <arm_group_label>Vago</arm_group_label>
    <arm_group_label>Cardia</arm_group_label>
    <arm_group_label>Healthy controls</arm_group_label>
    <other_name>Panodil</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Saline</intervention_name>
    <description>Saline (isotonic NaCl) will be infused intravenously during the four hour meal test (100 g Ny NAN1 and 1.5 g paracetamol dissolved in 300 ml water) ingested over 10 minutes.
After four hours an ad libitum meal will be supplied</description>
    <arm_group_label>Vago</arm_group_label>
    <arm_group_label>Cardia</arm_group_label>
    <arm_group_label>Healthy controls</arm_group_label>
    <other_name>Panodil</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  truncal vagotomy

          -  normal hemoglobin

          -  informed consent

          -  Age, gender and weight matched controls

          -  normal hemoglobin

          -  informed consent

        Exclusion Criteria:

          -  type 1 diabetes mellitus or type 2 diabetes mellitus

          -  body mass index &gt; 30 kg/m2

          -  inflammatory bowel disease

          -  intestinal resection

          -  nephropathy (serum creatinine &gt; 150 µM and/or albuminuria)

          -  liver disease (ALAT and/or ASAT &gt; 2 x normal value)

          -  treatment with medicine which cannot be paused for 12 hours
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Astrid Plamboeck, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Gentofte, Copenhagen</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Tina Vilsbøll, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>University Hospital, Gentofte, Copenhagen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Internal Medicine F' laboratory</name>
      <address>
        <city>Hellerup</city>
        <state>Copenhagen</state>
        <zip>2900</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>December 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 5, 2010</study_first_submitted>
  <study_first_submitted_qc>August 5, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 6, 2010</study_first_posted>
  <last_update_submitted>December 6, 2012</last_update_submitted>
  <last_update_submitted_qc>December 6, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 7, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital, Gentofte, Copenhagen</investigator_affiliation>
    <investigator_full_name>Jonatan I Bagger</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>truncal vagotomy</keyword>
  <keyword>GLP-1</keyword>
  <keyword>gastric emptying</keyword>
  <keyword>appetite</keyword>
  <keyword>food intake</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glucagon-Like Peptide 1</mesh_term>
    <mesh_term>Glucagon</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

